Physician profile
Evan S Loft
NPI 1750407839
$2,441.38
in general payments reported to CMS, 2019-2025
22 companies · $474 in 2025
The $474 reported for 2025 was less than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $315 · 2021: $378 · 2022: $245 · 2023: $390 · 2024: $216 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $386.57 | 2019-2023 | |
| Alcon Vision LLC | $349.32 | 2019-2025 | Voyager Dslt, Hydrus Microstent, Clareon |
| Carl Zeiss Meditec USA, INC. | $228.24 | 2021-2025 | Lumera 700, Callisto Eye, Quatera 700 |
| Johnson & Johnson Surgical Vision, INC. | $199.08 | 2019-2025 | Veritas Vision System |
| Glaukos Corporation | $174.10 | 2023-2024 | Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Allergan, INC. | $146.86 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $135.86 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $115.93 | 2023-2025 | Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.92 | 2019-2021 | |
| Horizon Therapeutics Plc | $96.54 | 2022 | |
| Sun Pharmaceutical Industries INC. | $81.52 | 2019-2023 | Cequa |
| Harrow Eye, LLC | $75.57 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $68.48 | 2024 | Xdemvy |
| Beaver-Visitec International, INC. | $55.85 | 2021 | |
| Abbvie INC. | $51.35 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $28.99 | 2021 | |
| Oyster Point Pharma, INC. | $28.80 | 2025 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $25.88 | 2019 | |
| Mallinckrodt Hospital Products INC. | $25.64 | 2020 | |
| Ocular Therapeutix, INC. | $19.31 | 2019 | |
| Medline Industries Lp | $15.85 | 2021 | |
| Shire North American Group INC | $15.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Loft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.